Using change in the National Institutes of Health stroke scale to measure treatment effect in acute stroke trials

Stroke

Volumn 37, Issue 3, 2006, Pages 920-921

  Bruno, Askiel ^a,b   Sana, Chandan ^a   Williams, Linda S ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

Outcome; Recovery of function; Stroke, acute

Indexed keywords

DANAPAROID; ANTICOAGULANT AGENT; CHONDROITIN SULFATE; DERMATAN SULFATE; HEPARAN SULFATE; PLACEBO;

ARTICLE; BARTHEL INDEX; CLINICAL FEATURE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; DISEASE ACTIVITY; DISEASE SEVERITY; GLASGOW COMA SCALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROBABILITY; STATISTICAL MODEL; STROKE; ACUTE DISEASE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; HEALTH CARE ORGANIZATION; HOSPITALIZATION; METHODOLOGY; PATHOLOGY; REGRESSION ANALYSIS; RISK; ROC CURVE; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES;

ACUTE DISEASE; ANTICOAGULANTS; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CHONDROITIN SULFATES; CLINICAL TRIALS; COHORT STUDIES; DATA INTERPRETATION, STATISTICAL; DERMATAN SULFATE; HEPARITIN SULFATE; HUMANS; NATIONAL INSTITUTES OF HEALTH (U.S.); ODDS RATIO; PLACEBOS; REGRESSION ANALYSIS; ROC CURVE; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UNITED STATES;

EID: 33645056479     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000202679.88377.e4     Document Type: Article

References (15)

1. Lai SM, Duncan PW. Stroke recovery profile and the Modified Rankin assessment. Neuroepidemiology. 2001;20:26-30.
2. Saver JL. Number needed to treat estimates incorporating effects over the entire range of clinical outcomes: novel derivation method and application to thrombolytic therapy for acute stroke. Arch Neurol. 2004;61:1066-1070.
3. Adams HP Jr, Leclerc JR, Bluhmki E, Clarke W, Hansen MD, Hacke W. Measuring outcomes as a function of baseline severity of ischemic stroke. Cerebrovasc Dis. 2004;18:124-129.
4. Young FB, Lees KR, Weir CJ. Improving trial power through use of prognosis-adjusted end points. Stroke. 2005;36:597-601.
5. Adams HP Jr, Davis PH, Leira EC, Chang KC, Bendixen BH, Clarke WR, Woolson RF, Hansen MD. Baseline NIH Stroke Scale score strongly predicts outcome after stroke: a report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Neurology. 1999;53:126-131.
6. Lyden P, Lu M, Jackson C, Marler J, Kothari R, Brott T, Zivin J. Underlying structure of the National Institutes of Health Stroke Scale: results of a factor analysis. NINDS tPA Stroke Trial Investigators. Stroke. 1999;30:2347-2354.
7. Brown DL, Johnston KC, Wagner DP, Haley EC Jr. Predicting major neurological improvement with intravenous recombinant tissue plasminogen activator treatment of stroke. Stroke. 2004;35:147-150.
8. Young FB, Weir CJ, Lees KR. Comparison of the National Institutes of Health Stroke Scale with disability outcome measures in acute stroke trials. Stroke. 2005;36:2187-2192.
9. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Low molecular weight heparinoid, ORG 10172 (Danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. J Am Med Assoc. 1998;279:1265-1272.
10. Diener HC, Hacke W, Hennerici M, Radberg J, Hantson L, De Keyser J. Lubeluzole in acute ischemic stroke. A double-blind, placebo-controlled phase II trial. Lubeluzole International Study Group. Stroke. 1996;27:76-81.
11. Grotta J. Lubeluzole treatment of acute ischemic stroke. The US and Canadian Lubeluzole Ischemic Stroke Study Group. Stroke. 1997;28:2338-2346.
12. Steiner T, Bluhmki E, Kaste M, Toni D, Trouillas P, von Kummer R, Hacke W. The ECASS 3-hour cohort. Secondary analysis of ECASS data by time stratification. ECASS Study Group European Cooperative Acute Stroke Study. Cerebrovasc Dis. 1998;8:198-203.
13. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998;352:1245-1251.
14. Lyden P, Shuaib A, Ng K, Levin K, Atkinson RP, Rajput A, Wechsler L, Ashwood T, Claesson L, Odergren T, Salazar-Grueso E. Clomethiazole Acute Stroke Study in ischemic stroke (CLASS-I): final results. Stroke. 2002;33:122-128.
15. Burger K, Jordan J, Moshier E, Godbold J, Brown DM, Levine S. The change in National Institutes of Stroke Scale score over time in the NINDS rt-PA Stroke Study. Stroke. 2005;36:494.